Vonoprazan Test for PPI Refractory GERD
Key facts
- Who runs it
- Fu Jen Catholic University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 100 people, planned
- Started
- 24 Dec 2025
- Planned end
- 28 Oct 2026
- Type of study
- Interventional
- Treatments tested
- Patients received a 4-week treatment of vonoprazan 20 mg once daily (VOCINTI®)
- Record updated
- 27 February 2026
Who can take part
- Age
- 20 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Patients aged between 20 and 75 years
- Outpatients at Fu Jen Catholic University Hospital who had undergone esophagogastroduodenoscopy (EGD) within the past year
- Presence of persistent GERD symptoms, including acid regurgitation, heartburn, chest pain, globus sensation, or chronic cough. PPI-refractory GERD, defined as persistent symptoms despite receiving at least 8 weeks of standard-dose proton pump inhibitor (PPI) therapy (GerdQ > = 8)
- Scheduled to undergo high-resolution manometry (HRM) and 24-hour esophageal pH-impedance monitoring
- Patients with a history of any grade of erosive esophagitis confirmed by gastroscopy
Who cannot take part
- patients currently taking atazanavir sulfate or rilpivirine hydrochloride,
- major esophageal motility disorders
- history of upper gastrointestinal surgery
- malignant tumors
- significant acute GI bleeding
- severe renal impairment (CrCl < 30 mL/min)
- hypersensitivity to vonoprazan or its excipients
- liver cirrhosis
- esophageal strictures
- esophageal varices
- gastrointestinal obstruction
- LA Grade B, C, or D erosive esophagitis,
- esophageal peptic stricture
- biopsy-proven Barrett's esophagus
- long-term dialysis, pregnancy
- dependent on tube feeding
- unable to cooperate due to impaired consciousness
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 20 and 75 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Among patients suffering from gastroesophageal reflux disease (GERD) symptoms, esophageal pH monitoring and the assessment of symptom-reflux correlation can identify two distinct subgroups characterized by normal acid exposure: functional heartburn and reflux hypersensitivity. Given the absence of abnormal acid exposure in these groups, conventional antacid therapies often yield unsatisfactory clinical outcomes.
Read full original descriptionShow less
Therefore, in cases of PPI-refractory GERD, it is hypothesized that patients with underlying abnormal acid reflux will respond to Vonoprazan, a more potent potassium-competitive acid blocker (P-CAB). Conversely, those whose symptoms are unrelated to acid reflux are expected to show poor response. For future refractory patients without definitive endoscopic evidence of GERD (such as Los Angeles Grade B, C, or D esophagitis, peptic stricture, or histologically confirmed Barrett's esophagus), a Vonoprazan therapeutic trial could potentially bypass the need for invasive high-resolution manometry (HRM) and 24-hour pH-impedance monitoring. Evaluating the efficacy of Vonoprazan may offer diagnostic insights while minimizing patient discomfort and reducing overall healthcare expenditures.
The group in the trial
- single arm. All patient received VonoprazanOther group
Patients scheduled for high-resolution manometry (HRM) and 24-hour esophageal pH-impedance monitoring due to GERD symptoms were invited to participate in this study. Following the attainment of informed consent, participants completed a series of GERD-related questionnaires on the day of their examination. Subsequently, they were prescribed a 4-week course of VOCINTI®, a potassium-competitive acid blocker (P-CAB), at a daily oral dose of vonoprazan 20 mg. At the 4-week follow-up visit, the clinical reports for HRM and 24-hour pH-impedance monitoring were reviewed. During this visit, patients completed the GERD-related questionnaires for a second time. Subsequent therapeutic management was then determined based on the comprehensive diagnostic results.
Treatment: Patients received a 4-week treatment of vonoprazan 20 mg once daily (VOCINTI®)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Vonoprazan Test for Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease
- Criteria questions
- Built from NCT07437768, who can take part
- Record updated
- 27 February 2026